Description: |
PSN632408 is an optimized agonist of GPR119 receptors that shows similar potency to OEA at both recombinant mouse and human GPR119 receptors, exhibiting EC50 values of 5.6 and 7.9 uM, respectively.
IC50 value: 5.6/7.9 uM ( recombinant mouse/ human GPR119)
Target: GPR119 agonist
Systemic administration of PSN632408 (30 mg/kgintraperitoneally) suppresses food intake, reduces weight gain, and white adipose tissue deposition in rats. GPR119 (previously designated SNORF25) is an orphan G protein-coupled receptor expressed predominantly in the pancreas and gastrointestinal tract in humans and in the brain, pancreas, and gastrointestinal tract in rodents. It mediates a reduction in food intake and body weight gain in rats upon treatment with oleoyl ethanolamide (OEA), an endogenous, potent agonist for PPARα. These data suggest that PSN632408 may be useful as a therapeutic agent for the treatment of obesity.
For the detailed information of PSN632408, the solubility of PSN632408 in water, the solubility of PSN632408 in DMSO, the solubility of PSN632408 in PBS buffer, the animal experiment (test) of PSN632408, the cell expriment (test) of PSN632408, the in vivo, in vitro and clinical trial test of PSN632408, the EC50, IC50,and affinity,of PSN632408, Please contact DC Chemicals. |